Abstract: Whether atypical antipsychotics (AAs) can enhance smoking reduction in schizophrenic patients remains controversial because of methodological limitations in existing studies. This study explored whether certain types of antipsychotics predict smoking reduction in schizophrenic patients. Three hundred eight smoking, predominantly male schizophrenic patients (271/308 [88.9%]) participated in an 8-week open-label study with antismoking medications (high-dose, low-dose nicotine transdermal patch and bupropion). Antipsychotics were classified into (1) typical antipsychotics (TAs) and (2) AAs, including multiacting receptor-targeted antipsychotics (clozapine, olanzapine, and quetiapine), serotonin-dopamine antagonists (risperidone), D2/D3 receptor antagonists (amisulpride), and partial dopamine receptor agonists (aripiprazole). A general linear model was used to explore whether types of antipsychotic predict changes in the number of cigarettes smoked per day (CPD) and the score of the Fagerstrom Test for Nicotine Dependence (FTND) while controlling for confounding factors. The type of antipsychotic (TAs or AAs) was not significantly associated with smoking cessation (n = 21; W 2 = 1.8; df = 4; P = 0.77). Regarding smoking reduction, the type of antipsychotic was significantly predictive of a change in the CPD (P = 0.027; partial eta square = 0.055) and FTND scores (P = 0.002; partial eta square = 0.073). The 95% confidence intervals of the estimated means of change in the CPD and FTND scores did not contain zero only among subjects on TAs or clozapine.
C ompared with the general population, patients with schizophrenia have higher smoking rates.
1,2 A meta-analysis of worldwide studies found that schizophrenic patients had a higher prevalence of ever smoking than the general population (odds ratio, 3.1; 95% confidence interval [CI], 2.4Y3.8). 3 The findings that patients with schizophrenia are more likely to smoke and have lower cessation rates may result from attentional impairments, 4 neurological deficits, 5 and developmental limbic abnormalities with respect to cortical-striatal mediation of the behavioral changes related to substance addiction, such as behavioral sensitization to nicotine use. 6, 7 There are several possible reasons for nicotine dependence in patients with schizophrenia: nicotine may reduce negative symptoms, akathisia, and other extrapyramidal adverse effects of antipsychotics 2,8Y10 ; it might ameliorate auditory gating impairments 1, 11, 12 ; and it might enhance the release of dopamine in the prefrontal cortex and nucleus accumbens. 13 Patients with schizophrenia typically have impairments in stress management skills and lack incentives to stop smoking, 14 decreasing their readiness to quit smoking. 15 Additionally, lower smoking cessation rates have been noted with pharmacological adjuvants such as nicotine replacement therapy (NRT) and bupropion 3,16Y19 in schizophrenic patients compared with the general population. Therefore, interest in finding the predictors of smoking cessation outcomes in this population has increased, 4, 5, 20, 21 with particular attention paid to the role of various antipsychotics. 22 Schizophrenic patients using nicotine patches and being treated simultaneously with atypical antipsychotics (AAs) seem to have increased smoking cessation rates. 18, 21, 23 In addition, clozapine, a unique type of AA, has been noted to reduce more expired carbon monoxide (CO) and to lower nicotine dependence rates in schizophrenic patients compared with other types of AAs and typical antipsychotics (TAs). 24, 25 Nonetheless, some studies could not validate the disadvantage of TAs for smoking reduction. 17, 26, 27 Because prior studies did not control for potential confounders, such as age, sex, smoking, clinical features, adverse effects caused by medication and antipsychotic dosage, their results are controversial. 18, 23, 28 Additionally, small sample sizes, 18, 21, 23, 25, 27, 29 cross-sectional methods, 8, 25, 30 the absence of a parallel control group for different types of antipsychotics, 27, 29, 31 heterogeneous diagnostic groups, 17 and varying measurements of outcomes 22, 32 are also potential limiting factors. Table 1 displays the limitations of prior studies regarding the types of antipsychotics and related smoking prevalence, cessation, or reduction in patients with schizophrenia.
Moreover, prior studies have been limited with regard to the comparison and classification of antipsychotics. Most authors have compared limited types of antipsychotics, such as clozapine versus TAs, 24, 27 clozapine versus risperidone, 25 or TAs versus AAs. 8, 18 More detailed classifications of antipsychotics have not been proposed in similar studies. Some authors have argued that the potent blocking effects of the 5-HT2 A receptor and weak dopamine D 2 receptor antagonism are the core pharmacologic characteristics that distinguish clozapine and other AAs from the typicals. 33Y35 On the other hand, some authors have proposed the ''fast-off'' hypothesis that a rapid dissociation of antipsychotics from the D 2 receptor at a molecular level characterizes the AAs. 36 Above all, it is largely accepted that clozapine, quetiapine, olanzapine, risperidone, sertindole, amisulpride, ziprasidone, and aripiprazole are categorized as AAs. 37Y41 However, 42 Hence, after a thorough process of contemplation and discussion, we essentially adopted the classification system of antipsychotics proposed by a review article in which the authors provided a clear rationale for their system based on a wide and comprehensive review of the literature. 38 Our pilot trial of smoking cessation with NRT, 43 which recruited 110 hospitalized male patients with schizophrenia smoking an average of 16 cigarettes per day, revealed that there were no significant differences in cessation rates between the TAs and AAs groups (W 2 = 2.6; df = 1; P = 0.106). However, there were significant differences in the rates of 50% reduction between the users of TAs (39.3% [11/28] ) and AAs (16% [12/75] ) (W 2 = 6.3; df = 1; P = 0.012). Accordingly, in the current study, we were interested in testing whether the type of antipsychotic predicts the smoking reduction outcomes among schizophrenic patients. The hypotheses to be tested were as follows: (1) whether patients on AAs are more likely to reduce and stop smoking than those on TAs and (2) whether patients on clozapine are more likely to reduce and stop smoking than those who are on nonclozapine atypical antipsychotics (NCAAs).
MATERIALS AND METHODS

Participants
We analyzed an open-label trial (N = 308) that was originally designed to explore the effects of different kinds of adjuvants on smoking cessation in schizophrenic patients. This study revealed that there were no significant differences in cessation rates among those taking various doses of NRT and bupropion. 44 This study was conducted from June 2005 to December 2007. Schizophrenic patients were recruited from the chronic wards of 2 public psychiatric hospitals in Hualien County, Taiwan. All of the participants gave informed consent. These studies were approved by the institutional review board of these 2 hospitals. We recruited only patients who met the diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and those who were regular daily smokers at the time of recruitment. Patients were excluded if (1) they had an acute exacerbation of psychosis that necessitated a transfer to the acute care wards for treatment of severe respiratory and heart diseases, or (2) they were concurrently on 2 kinds of AAs or a regimen of TAs and AAs. Three types of medications for smoking reduction were administered: high-dose NRT (31.2 mg for the first 4 weeks, then 20.8 mg for weeks 5 to 8; n = 80), lowdose NRT (20.8 mg for 8 weeks; n = 152), or oral use of bupropion (150 mg/d; n = 76). All of the patients were allowed to smoke at will between 6:00 AM and 9:30 PM, as long as they obtained their lighters and cigarettes from the medical staff. Six sessions of simple psychoeducation (20 minutes per session, 2 sessions per week) for smoking cessation, including topics, such as the physical harm caused by smoking and the benefits of smoking cessation, were provided after the initiation of the clinical trial.
Classification of Antipsychotics
The antipsychotics were categorized according to the classification of a review article. 38 Risperidone was categorized with serotonin-dopamine antagonists, which have a high selectivity for D 2 
Measures
We collected data regarding demographic features, tobacco smoking, and clinical features related to schizophrenia. The level of nicotine dependence was assessed using the modified Fagerstrom Test for Nicotine Dependence (FTND) 54 translated into Chinese. 55 The patients' clinical symptoms were rated using a Chinese version 56 of the Positive and Negative Syndrome Scale. 57 The patients' neuroleptic-induced Parkinsonism was assessed using the Simpson-Angus Rating Scale. 58 Readiness to quit smoking was assessed based on the transtheoretical theory, which postulates 3 stages representing the level of readiness to quit, in ascending order: precontemplation, contemplation, and preparation. 59 We converted daily doses of antipsychotics to approximate daily mean chlorpromazine milligram equivalents according to standard guidelines. 48, 60, 61 We used an EC50 Micro III Smokerlyzer (Bedfont Scientific Ltd, Rochester, UK) to measure the end-tidal breath CO levels before and at the end of the trial.
Outcomes
We chose smoking cessation as the primary outcome measure, that is, 7-day smoking abstinence defined as self-reported zero cigarette in the preceding 7 days plus an expired CO level of less than 10 ppm. 18 However, our pilot trial of smoking cessation with NRT revealed that the 7-day point prevalence of abstinence at 8 weeks was only 0.9% (1/110). 43 Thus, we chose smoking reduction as our secondary outcome, which was defined as a change in the self-reported number of cigarettes smoked per day (CPD) and a change in the FTND score at the 8-week end point. The intent-to-treat approach was adopted for the analysis. Those who withdrew from the study were treated as failing to achieve cessation. Their end-point CPD and FTND scores were coded to be the same as before the initiation of the trial.
Comparison of Smoking Reduction Effects
Because smoking reduction effects can be accounted for by changes in the CPD and FTND, 20 we adopted the following criteria regarding comparisons of the smoking reduction effects between types of antipsychotics:
1. Post hoc comparison of a change in the CPD or FTND: during the pairwise comparison, if the mean reduced CPD or FTND for subjects on a given medication were significantly greater than on another medication, the score for this given medication would be denoted as 1. If no difference was present, the score would be zero; if the score was significantly lower than for another medication, then it would be denoted as j1. The final comparison score for the CPD or FTND for a given medication was the summation of all the comparison scores. 2. Score for a reduction in the CPD (CPD-R) or score for a reduction in the FTND: this score depended on whether the 95% CI of the estimated means of change in the CPD or FTND contained zero. If it did, it meant that there was no significant change in the CPD or FTND after the trial and the score would be denoted as 0. If the value of mean difference was negative and the 95% CI did not contain zero in the 95% CI, it indicated that those who were on this medication show greater reductions in the CPD or FTND after the trial; therefore, the score was denoted as 1. If the value of mean difference was positive and the 95% CI did not contain zero, it indicated that those who were on this medication showed greater increases in the CPD or FTND after the trial; therefore, the score was denoted as j1. 3. Four sets of scores (comparison score for CPD, comparison score for FTND, reduction score for CPD-R, and reduction score for FTND) would be summed into a total reduction score for each medication in all classifications. In a given classification system (classes 1Y3) and for a given kind of antipsychotic, higher scores indicated a greater effect of the antipsychotic on smoking reduction. Table 2 displays the scoring rules. 4. For a given medication, if the values of estimated means of change in both the CPD and the FTND were negative, and the 95% CI of the estimated means of change in both the CPD and the FTND did not contain zero, this finding indicated that users of this type of antipsychotic had the capability for significant smoking reduction.
Statistical Analysis
First, we tested the representativeness of the subjects entered into the analyses by comparing the differences between those participants who withdrew from the study and those who remained using independent t tests for continuous variables and W 2 tests for categorical variables. Group differences among antipsychotics were assessed using an analysis of variance for baseline continuous variables and the change in the CPD at the end point. Chi-squared tests were used for categorical variables (medications for smoking reduction, sex, and readiness to quit). A general linear regression model was used to examine the association between antipsychotic type and smoking reduction outcomes (change in CPD/change in FTND). Potential confounders related to smoking in prior studies were controlled for. These included age, sex, antipsychotic type, medications for smoking reduction (low-dose NRT, high-dose NRT, and bupropion), extent of neuroleptic-induced extrapyramidal symptoms (SimpsonAngus Rating Scale), 10 severity of negative symptoms and positive symptoms, 2,9 antipsychotic dose, 28 CPD, and FTND. 62 The estimated means of the CPD and FTND score among the groups of antipsychotics were compared pairwise using a Bonferroni correction. Smoking cessation outcomes the among groups of antipsychotics were compared with a W 2 test. Statistical Package for the Social Sciences version 11.5 (SPSS Inc, Chicago, IL) was used for the statistical analyses. The significance level was set at P = 0.05 (2 tailed).
RESULTS
Participants and Types of Antipsychotics
Most of the subjects were male patients (271/308 [88.9%]). The mean (SD) age of the patients was 48.6 (10) years. Overall, 64 (21%) of the 308 participants withdrew from the trial. The participants who withdrew from the trial were older at the onset *Mean difference of change in the CPD ($CPD) between 2 medications is equal to the value of $CPD of former medication minus the value of $CPD of latter medication; negative value for mean difference indicates that the former medication reduces more cigarettes than the latter one; positive value for mean difference indicates that the former medication reduces fewer cigarettes than the latter one.
of smoking (24.3 vs 20.3; P = 0.011) and had smoked for a greater number of years (26.8 vs 23; P = 0.025). There were no other significant differences between the 2 groups. Table 3 shows detailed information concerning antipsychotic use. Table 4 shows the demographic, clinical, and smoking characteristics of the schizophrenic patients on different types of antipsychotics. The participants on clozapine were younger, and those on TAs were older than those on other antipsychotics. Those who were on olanzapine or quetiapine were all male. Those on TAs had more severe extrapyramidal symptoms. The patients on aripiprazole or risperidone were likely to have more severe positive subscale scores. The participants who were taking amisulpride appeared to be younger at the onset of smoking and to be on higher dosages of antipsychotics. Otherwise, the patients on various types of antipsychotics did not differ from one another in clinical history or smoking characteristics.
Outcome of Smoking Cessation
Overall, 21 (7%) of the 308 patients met the criteria for 7-day smoking abstinence. The participants who achieved cessation were the following: in class 1, 12 participants were on TAs (8.3%) and 9 participants were on AAs (5.6%); in class 2, 12 participants were on TAs (8.5%), 3 participants were on AAs (3.9%) and 6 participants were on clozapine (7.9%); in class 3, 12 participants were on TAs (8.5%), 1 participant was on risperidone (3.6%), 6 participants were on clozapine (7.4%), 1 participant was on aripiprazole (12.5%), 1 participant was on NC-MARTA (3.4%), and none were on amisulpride. For all classifications, there were no significant differences in abstinence rates among the participants taking different types of antipsychotics (class 1: W 2 = 0.89, df = 1, P = 0.34; class 2: Table 4 illustrates that the mean (SE) change in the CPD was 2.3 (7.1), and change in the FTND was 1.5 (2.6). Table 5 shows the comparison of smoking reduction effects among the types of antipsychotics. Using a general linear model, in all classifications, the between-subjects effects showed that antipsychotic type was significantly predictive of changes in the CPD (class 1: df = 1, F = 5.5, P = 0.019; class 2: df = 2, F = 4.2, P = 0.016; class 3: df = 5, F = 2.5, P = 0.031) and FTND (class 1: df = 1, F = 4.2, P = 0.04; class 2: df = 2, F = 5.3, P = 0.005; class 3: df = 5, F = 3.4, P = 0.005). The effect sizes for change in the CPD or FTND, represented by partial eta square, ranged from 0.023 to 0.073. The total reduction scores for the reduction effects in the TAs were the greatest in all classifications. For users of TAs or clozapine, neither the 95% CI of the means of change in the CPD nor that of the FTND contains zero in all classifications. In class 3, the total reduction score for the TAs was equal to that of clozapine (total reduction score, 3) and was followed by the scores for aripiprazole and the NC-MARTAs (total reduction score, 1), amisulpride (total reduction score, 0) and risperidone (total reduction score, j2).
Outcome of Smoking Reduction
In addition to antipsychotic type, the covariates, which significantly predicted change in the CPD or FTND, were age, sex, medications for smoking reduction, CPD at week zero, FTND score at week zero, and readiness to quit (data not shown). Detailed information was not reported and is discussed here because the exploration of multiple predictors of smoking reduction was not the main aim of this study.
DISCUSSION
Types of Antipsychotics and Smoking Reduction Outcomes
Regarding the primary outcome, because a small number of patients quit smoking (n = 21), any meaningful inferences regarding abstinence cannot be established. Regarding smoking reduction, antipsychotics categorized into 2 types (class 1: TAs and AAs), 3 types (class 2: TAs, clozapine, NCAAs), and 6 types (class 3: TAs, clozapine, and the other 4 types of NCAAs) 
Smoking Reduction Effect Between TAs and AAs, and NCAAs and Clozapine
For our first question, we did not have enough evidence to conclude that the subjects on AAs have a higher probability of smoking reduction or cessation compared with those on TAs. Instead, the subjects on TAs reduce more smoking than those on AAs, yet the effect size for change in the CPD or FTND was small (partial eta square ranged from 0.018 to 0.023). These results were consistent with the finding of a previous large study of psychotic patients showing no significant differences in smoking cessation or 50% smoking reduction between groups of patients on TAs and AAs. 17 However, our findings differed from many studies reporting that AAs help schizophrenic patients smoke fewer cigarettes compared to TAs. 1, 8, 18, 23, 24 The disparity might be explained by the fact that prior studies tended to have the following limitations: small sample sizes, no adjustment for potential confounders, lack of control groups for TAs to confirm the superiority of AAs in smoking cessation, and the use of cross-sectional study designs. For example, one study, which was limited by the use of a cross-sectional design, suggested that clozapine was superior to TAs in smoking reduction, showing that patients on clozapine had significantly lower levels of expired carbon monoxide and self-reported CPD than those on depot neuroleptics. 24 In contrast to our findings, a study of 32 schizophrenic outpatients with nicotine dependence randomized to bupropion (300 mg/d) or placebo found higher cessation rates in users of AAs (clozapine, olanzapine, and risperidone) compared to users of TAs: 66.7% (8/12) versus 0% (0/4) in the bupropion group and 20.0% (2/10) versus 0% (0/6) in the placebo group. 23 The smoking reduction effect of AAs seemed to be greater than that of TAs. Possible explanations for the discrepancies between this study and ours could be the use of outpatients versus inpatients (community vs institutionalized status), variations in the readiness to quit (mostly strong desire to quit vs 40% in the preparation stage), and different psychosocial interventions (motivational enhancement and relapse prevention strategies vs simple psychoeducation). However, in that study, the small sample sizes and lack of a control for confounders limited the generalizability. On the other hand, a study that tried to control for the aforementioned confounders and randomized 4 types of antipsychotics (haloperidol, risperidone, aripiprazole, and olanzapine) into antipsychotic-free schizophrenic outpatients with nicotine dependence revealed that the users of haloperidol compared with AAs increased nicotine dependence after an 8-week follow-up. However, the interpretation of results in this study was limited by the lack of a double-blind assessment and the use of uncommonly used measures of smoking outcomes, such as a 7-point visual-analog rating scale for cigarette cravings and the Fagerstrom Tolerance Questionnaire instead of the FTND and CPD. 32 For the second question, our results suggested that patients on clozapine smoked less than those on NCAAs. One study, which mirrored our findings, revealed that schizophrenic patients on clozapine and risperidone smoked significantly less than those on risperidone alone. 25 Our findings are also consistent with studies that found that in patients with schizophrenia or other psychotic disorders, clozapine seems to be the most effective antipsychotic compared with NCAAs for decreasing the use of cocaine, cannabis, and alcohol. 64, 65 Type of Antipsychotic and the Dopaminergic Reward System
The superiority of TAs over NCAAs for smoking reduction could be explained in part by a study that found that healthy volunteers on a higher dose of haloperidol smoked less than those on a lower dose. 26 In that study, the authors suggested that the level of antipsychotic caused a blockade of the dopaminemediated reinforcing effects of smoking, which in turn may affect smoking behavior. This hypothesis is also consistent with the findings of another study showing that 20 smokers acutely treated with haloperidol reduced the cue-elicited urge to smoke. 66 Drug abusers, a population found to have low availability of the D 2 /D 3 receptor in the dorsal striatum, are more likely to relapse. 67 In heavy smokers, low striatal D 2 /D 3 receptor availability, especially in the nucleus accumbens after 24 hours of abstinence, correlated positively with the nicotine dependence level. 68 The authors in that study suggested that low D 2 /D 3 receptor availability may result from prolonged nicotine-induced dopamine release, which might partly explain why it is so hard for smokers remain abstinent. Finally, a functional magnetic resonance imaging study revealed that during reward anticipation, patients with schizophrenia taking TAs, but not olanzapine, had reduced left ventral striatal activation. 69 Therefore, after reviewing the previous studies, we hypothesized that TAs and AAs, which have different antagonistic effects on dopamine receptors, differ in their ability to block the reinforcing effects of smoking. Compared with TAs, AAs have a higher affinity for 5HT-2 A than for D 2 receptors, which indirectly release dopamine. 34, 70 Additionally, AAs block striatal D 2 receptors less and show weaker binding to D 2 receptors, thus inhibiting the reward system to a lesser degree than the TAs. 71 Consequently, unlike the AAs, the greater antagonistic effects of TAs on the D 2 receptors in the striatum, especially the nucleus accumbens, might decrease the rewarding effects of † Types of antipsychotics were significantly predictive of $CPD or $FTND (P = 0.05). ‡ Significant difference in means of $CPD between groups. § Significant difference in means $FTND between groups. || The 95% CI of the estimated means of $CPD and $FTND did not contain zero. ¶ Either the 95% CI of estimated means of $CPD or that of the FTND for a given medication contains zero. Covariates were adjusted for age, sex, severity of negative and positive symptoms, medications for smoking reduction, readiness to quit smoking, CPD at week 0, FTND at week 0, level of extrapyramidal symptoms, and antipsychotic dosage.
nicotine-induced dopamine release, leading to greater smoking reduction. In contrast with our hypothesis, another study revealed that while heavy smokers smoked faster, their craving score for nicotine increased significantly more and their total puffing time was longer with haloperidol compared with bromocriptine. 72 These findings implied that stimulation of the dopaminergic system would cause smoking reduction. Additionally, researchers have suggested that AAs may help increase the release of dopamine in the prefrontal cortex and reduce the deficit syndrome related to schizophrenia, leading to smoking reduction. 23 This hypothesis is at odds with our speculation that TAs favor smoking reduction possibly by enhancing the blockade of the dopaminergic rewarding effect compared to AAs. Yet, because the role of antipsychotics in smoking reduction in schizophrenia remains unclear and controversial findings have been reported in this field, further studies are needed to more fully elucidate these issues.
In our study, subjects on TAs or clozapine significantly reduced smoking. This finding is consistent with one study, which found that patients on haloperidol did not significantly reduce smoking while switching to clozapine. 27 Still, an explanation for the absence of significant differences between TAs and clozapine users with regard to smoking reduction remains a great challenge. Researchers have found that N-desmethylclozapine (NDMC), the principal metabolite of clozapine, a potent and efficacious muscarinic receptor agonist with unique molecular properties, is the specific molecular agent responsible for the distinctive efficacy of clozapine in the treatment of refractory schizophrenic patients. 73 N-desmethylclozapine has been found to alter hippocampal neurons in animal models, and schizophrenic patients with high NDMC/clozapine ratios are more likely to show improved cognitive functioning and quality of life. 72 The unique efficacy of clozapine in the treatment of substance dependence disorders compared to NCAAs 63,64 might be explained partly by the special molecular structure of NDMC, which is not found in any of the NCAAs. The TAs and clozapine may have comparable effects on smoking reduction because TAs block the reward system mediated by dopamine more completely and because clozapine has the distinctive features of NDMC. Both of these mechanisms may contribute equally to the superiority to NCAAs on smoking reduction.
Limitations of This Study
There are several limitations of our research. First, the generalization of the findings may be limited to populations with a similar nature, such as institutionalized schizophrenic patients in Taiwan who are predominantly men without a strong readiness to quit smoking. Second, in the current study, recruiting inpatients to determine the effects of antipsychotics on smoking behaviors may have limited the generalizability of our findings because the smoking access of patients in psychiatric hospitals is often limited by the rules of clinical settings. For example, smoking was not allowed in the current study from bedtime to the next morning, and access to cigarettes and lighters was restricted; these restrictions are uncommon for patients in community or daycare centers. 19, 74 Besides, patients who live outside the hospital do not receive the frequent advice given to inpatients by nurses to stop smoking. 75 In addition, the smoking intervention program was also different from the programs in some studies that required subjects to set a quit date. 18, 76 Regarding methodology, although we used a regression model with adjustments for many possible confounders and had a large sample size that might compensate for methodological shortcomings, leading to a relatively robust conclusion, our study was still not comparable to a randomized controlled trial, with randomization by antipsychotic type. 32 Finally, we propose that future researchers conduct studies with a longer follow-up period (eg, more than 3 months) using a double-blind controlled randomization of antipsychotic type and recruit a larger and more varied population, including patients living in the community, residing in rehabilitation centers, or engaging in supported occupational programs.
CONCLUSIONS
In summary, with a cohort of schizophrenic patients who received smoking cessation interventions, our findings suggest that the type of antipsychotic is predictive of smoking reduction but not cessation, possibly owing to the dearth of successful quitters. Schizophrenic patients on TAs or clozapine had a greater probability of achieving smoking reduction than those who were on NCAAs. The findings of this study raise questions about the possible roles of antipsychotics in mediating some of the effects of smoking, that is, the blockade of the rewarding effects of smoking. However, based on the available data, a clear understanding of the mechanisms involved in the effects of antipsychotics on smoking reduction is still lacking. Future studies are needed to explore this issue in more detail.
